- Home
- STTK vs TEAF Comparison
STTK vs TEAF Comparison
Compare STTK & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TEAF
- Stock Information
- Founded
- STTK 2016
- TEAF 2017
- Country
- STTK United States
- TEAF United States
- Employees
- STTK N/A
- TEAF N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- STTK Health Care
- TEAF Finance
- Exchange
- STTK Nasdaq
- TEAF Nasdaq
- Market Cap
- STTK 112.6M
- TEAF 167.4M
- IPO Year
- STTK 2020
- TEAF N/A
- Fundamental
- Price
- STTK $2.01
- TEAF $12.23
- Analyst Decision
- STTK Hold
- TEAF
- Analyst Count
- STTK 5
- TEAF 0
- Target Price
- STTK $3.00
- TEAF N/A
- AVG Volume (30 Days)
- STTK 196.6K
- TEAF 56.1K
- Earning Date
- STTK 11-06-2025
- TEAF 01-01-0001
- Dividend Yield
- STTK N/A
- TEAF 9.20%
- EPS Growth
- STTK N/A
- TEAF N/A
- EPS
- STTK N/A
- TEAF N/A
- Revenue
- STTK $1,000,000.00
- TEAF N/A
- Revenue This Year
- STTK N/A
- TEAF N/A
- Revenue Next Year
- STTK N/A
- TEAF N/A
- P/E Ratio
- STTK N/A
- TEAF N/A
- Revenue Growth
- STTK N/A
- TEAF N/A
- 52 Week Low
- STTK $0.69
- TEAF $11.11
- 52 Week High
- STTK $2.71
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- STTK 50.71
- TEAF 56.09
- Support Level
- STTK $1.86
- TEAF $12.30
- Resistance Level
- STTK $2.08
- TEAF $12.60
- Average True Range (ATR)
- STTK 0.14
- TEAF 0.12
- MACD
- STTK -0.00
- TEAF 0.02
- Stochastic Oscillator
- STTK 65.91
- TEAF 51.49
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Sustainable and Social Impact Term Fund Formerly Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.